Neuromodulation for Refractory Epilepsy

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Neuromodulation for Refractory Epilepsy. / Ryvlin, Philippe; Jehi, Lara E.

I: Epilepsy Currents, Bind 22, Nr. 1, 2022, s. 11-17.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Ryvlin, P & Jehi, LE 2022, 'Neuromodulation for Refractory Epilepsy', Epilepsy Currents, bind 22, nr. 1, s. 11-17. https://doi.org/10.1177/15357597211065587

APA

Ryvlin, P., & Jehi, L. E. (2022). Neuromodulation for Refractory Epilepsy. Epilepsy Currents, 22(1), 11-17. https://doi.org/10.1177/15357597211065587

Vancouver

Ryvlin P, Jehi LE. Neuromodulation for Refractory Epilepsy. Epilepsy Currents. 2022;22(1):11-17. https://doi.org/10.1177/15357597211065587

Author

Ryvlin, Philippe ; Jehi, Lara E. / Neuromodulation for Refractory Epilepsy. I: Epilepsy Currents. 2022 ; Bind 22, Nr. 1. s. 11-17.

Bibtex

@article{52434532fa8242058e2c8db3c078a202,
title = "Neuromodulation for Refractory Epilepsy",
abstract = "Three neuromodulation therapies, all using implanted device and electrodes, have been approved to treat adults with drug-resistant focal epilepsy, namely, the vagus nerve stimulation in 1995, deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) in 2018 (2010 in Europe), and responsive neurostimulation (RNS) in 2014. Indications for VNS have more recently extended to children down to age of 4. Limited or anecdotal data are available in other epilepsy syndromes and refractory/super-refractory status epilepticus. Overall, neuromodulation therapies are palliative, with only a minority of patients achieving long-term seizure freedom, justifying favoring such treatments in patients who are not good candidates for curative epilepsy surgery. About half of patients implanted with VNS, ANT-DBS, and RNS have 50% or greater reduction in seizures, with long-term data suggesting increased efficacy over time. Besides their impact on seizure frequency, neuromodulation therapies are associated with various benefits and drawbacks in comparison to antiseizure drugs. Yet, we lack high-level evidence to best position each neuromodulation therapy in the treatment pathways of persons with difficult-to-treat epilepsy.",
keywords = "deep brain stimulation, drug-resistant epilepsy, neuromodulation, responsive neurostimulation, vagus nerve stimulation",
author = "Philippe Ryvlin and Jehi, {Lara E.}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2021.",
year = "2022",
doi = "10.1177/15357597211065587",
language = "English",
volume = "22",
pages = "11--17",
journal = "Epilepsy Currents",
issn = "1535-7597",
publisher = "American Epilepsy Society",
number = "1",

}

RIS

TY - JOUR

T1 - Neuromodulation for Refractory Epilepsy

AU - Ryvlin, Philippe

AU - Jehi, Lara E.

N1 - Publisher Copyright: © The Author(s) 2021.

PY - 2022

Y1 - 2022

N2 - Three neuromodulation therapies, all using implanted device and electrodes, have been approved to treat adults with drug-resistant focal epilepsy, namely, the vagus nerve stimulation in 1995, deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) in 2018 (2010 in Europe), and responsive neurostimulation (RNS) in 2014. Indications for VNS have more recently extended to children down to age of 4. Limited or anecdotal data are available in other epilepsy syndromes and refractory/super-refractory status epilepticus. Overall, neuromodulation therapies are palliative, with only a minority of patients achieving long-term seizure freedom, justifying favoring such treatments in patients who are not good candidates for curative epilepsy surgery. About half of patients implanted with VNS, ANT-DBS, and RNS have 50% or greater reduction in seizures, with long-term data suggesting increased efficacy over time. Besides their impact on seizure frequency, neuromodulation therapies are associated with various benefits and drawbacks in comparison to antiseizure drugs. Yet, we lack high-level evidence to best position each neuromodulation therapy in the treatment pathways of persons with difficult-to-treat epilepsy.

AB - Three neuromodulation therapies, all using implanted device and electrodes, have been approved to treat adults with drug-resistant focal epilepsy, namely, the vagus nerve stimulation in 1995, deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) in 2018 (2010 in Europe), and responsive neurostimulation (RNS) in 2014. Indications for VNS have more recently extended to children down to age of 4. Limited or anecdotal data are available in other epilepsy syndromes and refractory/super-refractory status epilepticus. Overall, neuromodulation therapies are palliative, with only a minority of patients achieving long-term seizure freedom, justifying favoring such treatments in patients who are not good candidates for curative epilepsy surgery. About half of patients implanted with VNS, ANT-DBS, and RNS have 50% or greater reduction in seizures, with long-term data suggesting increased efficacy over time. Besides their impact on seizure frequency, neuromodulation therapies are associated with various benefits and drawbacks in comparison to antiseizure drugs. Yet, we lack high-level evidence to best position each neuromodulation therapy in the treatment pathways of persons with difficult-to-treat epilepsy.

KW - deep brain stimulation

KW - drug-resistant epilepsy

KW - neuromodulation

KW - responsive neurostimulation

KW - vagus nerve stimulation

U2 - 10.1177/15357597211065587

DO - 10.1177/15357597211065587

M3 - Review

C2 - 35233189

AN - SCOPUS:85121564224

VL - 22

SP - 11

EP - 17

JO - Epilepsy Currents

JF - Epilepsy Currents

SN - 1535-7597

IS - 1

ER -

ID: 313777412